GCLC and breast cancer: x) In breast cancer, Nrf2 serves as a key regulator in chemotherapeutic resistance under hypoxia through ROS-Nrf2-GCLC-GSH pathway and can be a potential treatment for hypoxia induced drug resistance in breast cancer cells (Song et al., 2011; Syu et al., 2016).